



PATENT

Docket No.: 20747/260 (ARDBW/P29267US)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Finn Larsen

Serial No. : 10/527,879

Cnfrm. No. : To Be Assigned

Filed : September 19, 2003

For : EFFERVESCENT FORMULATIONS OF  
OXYTOCINExaminer:  
To Be AssignedArt Unit:  
To Be AssignedSUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.97-1.98**Mail Stop: Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:


Pursuant to 37 CFR §§ 1.97-1.98, applicant hereby brings to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO/SB/08 form.

Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), a copy of the cited U.S. Patent (i.e., Reference Cite No. 1) is not enclosed. Copies of all other listed references (i.e., Reference Cite Nos. 2-9) are enclosed herewith.

Pursuant to 37 CFR § 1.97(b)(3), no fee is required. If additional fees are required, however, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 14-1138.

Respectfully submitted,

Date: August 25, 2005

  
Edwin V. Merkel  
Registration No. 40,087

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1128  
Facsimile: (585) 263-1600

R871468.1

**Certificate of Mailing - 37 CFR 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents P.O. Box 1450  
Alexandria, VA 22313-1450, on the date below.

Date 8/25/05   
Mary Burke



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/527,879	
				Filing Date	September 19, 2003	
				First Named Inventor	Finn Larsen	
				Art Unit	To Be Assigned	
				Examiner Name	To Be Assigned	
Sheet	1	of	1	Attorney Docket Number	20747/260 (ARDBW/P29267US)	
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	U.S. Patent Document Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1	US-6,210,711 B1	04-03-2001	Aiache et al.		
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	2	EP 0 505 319 B1	09-23-1992	Jones et al.		
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
	3	ALFIREVIC & WALKINSHAW, "Management of Post-Term Pregnancy: To Induce or Not?" <i>Br. J. Hosp. Med.</i> 52(5):218-221 (1994)				
	4	GIRALDI et al., "Oxytocin and the Initiation of Parturition," <i>Dan. Med. Bull.</i> 37(4):377-383 (1990)				
	5	KELLY & TAN, "Intravenous Oxytocin Alone for Cervical Ripening and Induction of Labour (Review)," <i>Cochrane Database Syst. Rev.</i> , John Wiley & Sons, Ltd., pp.1-308 (2005)				
	6	LUCKAS & BRICKER, "Intravenous Prostaglandin for Induction of Labour (Review)," <i>Cochrane Database Syst. Rev.</i> , John Wiley & Sons, Ltd., pp.1-69 (2005)				
	7	MARTINDALE, "The Complete Drug Reference," Pharmaceutical Press, London, Sweetman eds., pp.1294-1295 (2002)				
	8	STUBBS, T.M., "Oxytocin for Labor Induction," <i>Clin. Obstet. Gynecol.</i> 43(3):489-494 (2000)				
	9	YUAN et al., "Synthesis and Pharmacological Evaluation of an Analogue of the Peptide Hormone Oxytocin That Contains a Mimetic of an Inverse $\gamma$ -Turn," <i>J. Med. Chem.</i> 45:2512-2519 (2002)				
Examiner Signature				Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.